NPPA directs strict monitoring of revised prices of 137 anti-cancer drugs

The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has directed strict monitoring of the implementation of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, with revised maximum retail prices (MRPs) coming into effect from November 9, 2026.

The revised prices were notified through a Gazette order dated October 17, 2026, the authority said.

The latest revised price lists, based on submissions received from pharmaceutical companies up to November 11, 2026, have been made available on the NPPA website and the Pharma Sahi Daam app and portal.

The NPPA has directed all manufacturers, retailers, dealers, stockists, hospitals and medical institutions to comply with the revised prices and prominently display updated price lists at their premises and on their websites.

State drug controllers asked to ensure compliance

State Drug Controllers (SDCs) have been instructed to closely monitor compliance by manufacturers, dealers, hospitals and medical institutions to ensure that the benefits of the revised prices are passed on to patients.

The authority warned that violations could invite proceedings for overcharging under the provisions of the Drugs (Prices Control) Order (DPCO), 2013.

Consumers can report complaints related to overcharging, shortage or non-availability of medicines through the Pharma Sahi Daam app or portal, the NPPA helpline at 1800-111-255, or by email at [email protected].

The NPPA has also directed State Drug Controllers to submit their action taken reports by November 16, 2026.

-PIB

The post NPPA directs strict monitoring of revised prices of 137 anti-cancer drugs appeared first on DD India.

Source link